Please assess the completion status of the following clinical trial:

Trial Title: Calcichew D3 Preference Study in Participants Eligible for Calcium and Vitamin D Supplementation.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.~2. Signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.~3. Is eligible for or currently receiving treatment with calcium and vitamin D supplement as determined by the treating clinician in accordance with local treatment guidelines.~4. Eligible participants will either be:~   1. Aged 65 years or older requiring calcium and vitamin D supplementation for the prevention or treatment of deficiencies, or~  2. Aged 18 years or older that require calcium and vitamin D as an adjunct to specific osteoporosis treatment in participants at risk of calcium and vitamin D deficiencies.~5. Is male or female.~6. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study, and for 12 weeks after last dose of study medication.~Exclusion Criteria:~1. Has received Calcichew D3, Adcal-D3 (if the participant is in Test Group 1) or Kalcipos-D (if the participant is in Test Group 2) within the 6 months prior to the first dose of study medication.~2. Has received any investigational compound within 30 days prior to Screening.~3. Has a disease and/or condition resulting in hypercalcaemia and/or hypercalciuria and for which the study drugs are contraindicated e.g. Zollinger-Ellison syndrome, nephrolithiasis.~4. Has any of the contraindications listed in the corresponding Summary of Product Characteristics (SPC) of the study drug that the participant may receive depending on the Test Group: Calcichew D3 or Adcal-D3 (if the participant is in Test Group 1); Calcichew D3 or Kalcipos-D (if the participant is in Test Group 2).~5. Is an immediate family member, study site employee, or is in a dependant relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.~6. Has a history of hypersensitivity or allergies to the active substances or to any of the excipients in the investigational products.~7. Has a history of known fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency.~8. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 12 weeks after participating in this study; or intending to donate ova during such time period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Test Group 1: Sequence AB (Type: EXPERIMENTAL): Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) \[A\], chewable tablets, orally, twice, daily, on Days 1 through 14, followed by Adcal-D3 (Calcium 600 mg / 400 IU Vitamin D3) \[B\], chewable tablets, orally, twice, daily, on Days 15 through 28.
- Test Group 1: Sequence BA (Type: EXPERIMENTAL): Adcal-D3 (Calcium 600 mg / 400 IU Vitamin D3), chewable tablets, orally, twice, daily, on Days 1 through 14, followed by, Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3), chewable tablets, orally, twice, daily, on Days 15 through 28.
- Test Group 2: Sequence CD (Type: EXPERIMENTAL): Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3) \[C\], chewable tablets, orally, once, daily, on Days 1 through 14, followed by Kalcipos-D (Calcium 500 mg/800 IU Vitamin D3) \[D\], chewable tablets, orally, once, daily, on Days 15 through 28.
- Test Group 2: Sequence DC (Type: EXPERIMENTAL): Kalcipos-D (Calcium 500 mg/800 IU Vitamin D3), chewable tablets, orally, once, daily, on Days 1 through 14, followed by, Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3), chewable tablets, orally, once, daily, on Days 15 through 28.

Based on this trial design, predict the completion outcome and termination type (if applicable).